Stock APRE APREA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.2 USD -2.80% Intraday chart for Aprea Therapeutics, Inc. -2.80% +10.64%
Apr. 10 Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024 CI
Mar. 27 Wedbush Raises Aprea Therapeutics' PT to $11 From $9 After Layering In Recent Financing, Maintains Outperform Rating MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 17.54 17.56 28.24 - -
Enterprise Value (EV) 1 17.54 17.56 28.24 28.24 28.24
P/E ratio -0.1 x -1.19 x -2 x -3.33 x -3.32 x
Yield - - - - -
Capitalization / Revenue - 30.1 x 141 x 141 x 141 x
EV / Revenue - 30.1 x 141 x 141 x 141 x
EV / EBITDA -0.15 x -1.14 x -1.38 x -1.21 x -1.07 x
EV / FCF -153,320 x - - - -
FCF Yield -0% - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 2,650 3,737 5,430 - -
Reference price 2 6.620 4.700 5.200 5.200 5.200
Announcement Date 3/30/23 3/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - - 0.5832 0.2 0.2 0.2
EBITDA 1 - -113.4 -15.46 -20.5 -23.4 -26.3
EBIT 1 - -113.4 -15.47 -19.19 -23.32 -29.33
Operating Margin - - -2,652.81% -9,594.66% -11,660% -14,664%
Earnings before Tax (EBT) 1 - -112.7 -14.29 -18.87 -23.28 -29.14
Net income 1 -37.13 -112.7 -14.29 -18.87 -23.28 -29.14
Net margin - - -2,449.59% -9,432.83% -11,637.66% -14,572.34%
EPS 2 -34.80 -67.99 -3.950 -2.597 -1.563 -1.567
Free Cash Flow - -114.4 - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/15/22 3/30/23 3/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - 0.2497 0.3195 - - - - 0.1967 -
EBITDA 1 - - -2.654 -4.622 -3.651 -3.521 -3.67 -4.6 -4.8 -5.5 -5.7 -
EBIT 1 -22.45 -4.2 -2.652 -4.622 -3.652 -3.523 -3.675 -4.352 -4.541 -4.92 -5.109 -5.49
Operating Margin - - - - -1,462.49% -1,102.72% - - - - -2,597.75% -
Earnings before Tax (EBT) 1 -98.26 -4.025 -2.442 -4.38 -3.259 -3.205 -3.443 -4.3 -4.6 -5.2 -5.3 -5.556
Net income 1 -98.26 -4.025 -2.442 -4.38 -3.259 -3.205 -3.443 -4.3 -4.6 -5.2 -5.3 -5.556
Net margin - - - - -1,305.26% -1,003.07% - - - - -2,694.87% -
EPS 2 -86.80 -2.400 -0.9200 -1.340 -0.8700 -0.8600 -0.9200 -0.7750 -0.8050 -0.8300 -0.5350 -1.000
Dividend per Share - - - - - - - - - - - -
Announcement Date 8/11/22 11/9/22 3/30/23 5/15/23 8/10/23 11/9/23 3/26/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -114 - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/15/22 3/30/23 3/26/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Aprea Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.2 USD
Average target price
15.67 USD
Spread / Average Target
+201.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
APREA THERAPEUTICS, INC. Stock Aprea Therapeutics, Inc.
+10.64% 28.24M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. APRE Stock
  4. Financials Aprea Therapeutics, Inc.